Why Your Specialty Drug Trend Number Hides the Real Cost

Specialty drugs account for a small share of prescriptions but a growing majority of pharmacy spend, and the gap keeps widening. According to Healthcare Dive, payers that lean on a headline specialty trend figure are missing the fuller picture of where and why costs rise.

The core problem is fragmentation. Many specialty therapies, especially infused and provider-administered drugs, are billed under the medical benefit rather than the pharmacy benefit. That split means a clean pharmacy trend number can look manageable while medical-benefit drug costs climb out of view. Site of care, rebate flows, and utilization patterns further complicate any single metric.

In practice, payers with a comprehensive view across both benefits can spot cost drivers earlier and steer patients toward lower-cost sites and appropriate therapies. The takeaway for plan sponsors and health plans: a rising or flat trend line alone says little. Understanding the underlying mix, channel, and administration setting is what actually enables management of specialty spend.